413 related articles for article (PubMed ID: 31631821)
1. Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases.
Gontijo VS; Viegas FPD; Ortiz CJC; de Freitas Silva M; Damasio CM; Rosa MC; Campos TG; Couto DS; Tranches Dias KS; Viegas C
Curr Neuropharmacol; 2020; 18(5):348-407. PubMed ID: 31631821
[TBL] [Abstract][Full Text] [Related]
2. Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer's Disease: An Update.
de Freitas Silva M; Dias KST; Gontijo VS; Ortiz CJC; Viegas C
Curr Med Chem; 2018; 25(29):3491-3525. PubMed ID: 29332563
[TBL] [Abstract][Full Text] [Related]
3. Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents.
Viegas FPD; Gontijo VS; de Freitas Silva M; Ortiz CJC; Dos Reis Rosa Franco G; Ernesto JT; Damasio CM; Silva IMF; Campos TG; Viegas C
Curr Neuropharmacol; 2022; 20(7):1297-1328. PubMed ID: 34825873
[TBL] [Abstract][Full Text] [Related]
4. The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease.
Mesiti F; Chavarria D; Gaspar A; Alcaro S; Borges F
Eur J Med Chem; 2019 Nov; 181():111572. PubMed ID: 31404859
[TBL] [Abstract][Full Text] [Related]
5. Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration.
Ramos E; Egea J; de Los Ríos C; Marco-Contelles J; Romero A
Future Med Chem; 2017 May; 9(8):765-780. PubMed ID: 28498717
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of Natural Products in Treating Neurodegenerative Disorders and Their Future Prospects and Challenges.
Rahman MH; Bajgai J; Fadriquela A; Sharma S; Trinh TT; Akter R; Jeong YJ; Goh SH; Kim CS; Lee KJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500759
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core.
Lin H; Li Q; Gu K; Zhu J; Jiang X; Chen Y; Sun H
Curr Top Med Chem; 2017; 17(27):3000-3016. PubMed ID: 28714419
[TBL] [Abstract][Full Text] [Related]
8. Natural products as a potential modulator of microglial polarization in neurodegenerative diseases.
Jin X; Liu MY; Zhang DF; Zhong X; Du K; Qian P; Gao H; Wei MJ
Pharmacol Res; 2019 Jul; 145():104253. PubMed ID: 31059788
[TBL] [Abstract][Full Text] [Related]
9. [Multifunctional ligands--a new approach in the search for drugs against multi-factorial diseases].
Wichur T; Malawska B
Postepy Hig Med Dosw (Online); 2015 Jan; 69():1423-34. PubMed ID: 27259214
[TBL] [Abstract][Full Text] [Related]
10. Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer's Disease.
Dias KS; Viegas C
Curr Neuropharmacol; 2014 May; 12(3):239-55. PubMed ID: 24851088
[TBL] [Abstract][Full Text] [Related]
11. The emergence of designed multiple ligands for neurodegenerative disorders.
Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
[TBL] [Abstract][Full Text] [Related]
12. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.
Geldenhuys WJ; Van der Schyf CJ
Expert Opin Drug Discov; 2013 Feb; 8(2):115-29. PubMed ID: 23231597
[TBL] [Abstract][Full Text] [Related]
13. Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.
Zindo FT; Joubert J; Malan SF
Future Med Chem; 2015; 7(5):609-29. PubMed ID: 25921401
[TBL] [Abstract][Full Text] [Related]
14. Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease.
Michalska P; Buendia I; Del Barrio L; Leon R
Curr Top Med Chem; 2017; 17(9):1027-1043. PubMed ID: 27697052
[TBL] [Abstract][Full Text] [Related]
15. Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).
Mishra P; Kumar A; Panda G
Bioorg Med Chem; 2019 Mar; 27(6):895-930. PubMed ID: 30744931
[TBL] [Abstract][Full Text] [Related]
16. Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders.
Baig MH; Ahmad K; Rabbani G; Danishuddin M; Choi I
Curr Neuropharmacol; 2018; 16(6):740-748. PubMed ID: 29046156
[TBL] [Abstract][Full Text] [Related]
17. Multitarget-directed ligands for neurodegenerative diseases: real opportunity or blurry mirage?
Benchekroun M; Maramai S
Future Med Chem; 2019 Feb; 11(4):261-263. PubMed ID: 30763133
[No Abstract] [Full Text] [Related]
18. New flavonoid -
Estrada-Valencia M; Herrera-Arozamena C; Pérez C; Viña D; Morales-García JA; Pérez-Castillo A; Ramos E; Romero A; Laurini E; Pricl S; Rodríguez-Franco MI
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):712-727. PubMed ID: 31852270
[TBL] [Abstract][Full Text] [Related]
19. Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment.
Minarini A; Milelli A; Tumiatti V; Rosini M; Simoni E; Bolognesi ML; Andrisano V; Bartolini M; Motori E; Angeloni C; Hrelia S
Neuropharmacology; 2012 Feb; 62(2):997-1003. PubMed ID: 22032870
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
